Regulatory Roles of Matrix Metalloproteinase-9 in Diabetic Cardiomyopathy

Diabetes mellitus (DM) is a chronic metabolic disorder characterized by hyperglycemia, hyperlipidemia, and impaired insulin signaling, leading to systemic metabolic disturbances that significantly elevate the risk of cardiovascular complications, including heart failure. Among these, diabetic cardiomyopathy poses a unique challenge due to complex metabolic perturbations and extensive cellular damage. In the diabetic heart, metabolic reprogramming increases reliance on fatty acid β-oxidation, intensifying mitochondrial stress and leading to energy deficits that accelerate heart failure progression. Despite extensive research on diabetes-induced heart failure, key gaps remain in understanding the molecular landscape—specifically, the interactions between metabolites, lipids, and proteins that drive cardiac dysfunction in diabetes. Increased fatty acid metabolism in the diabetic heart contributes to lipotoxicity, a major driver of cardiac dysfunction through mechanisms beyond simple lipid accumulation. While apoptosis has a limited role in heart failure, non-apoptotic cell death, particularly ferroptosis, is increasingly recognized as central to cardiomyocyte loss in diabetes. Excessive lipids and iron synergistically foster a pro-ferroptotic environment, characterized by heightened lipid peroxidation and reactive oxygen species (ROS) accumulation. Given the heart's limited regenerative capacity, ferroptosis emerges as a vital yet underexplored pathway in diabetic cardiomyopathy, presenting promising avenues for therapies aimed at reducing myocardial cell death and preserving cardiac function. Matrix metalloproteinases (MMPs), a family of enzymes involved in extracellular matrix remodeling, play regulatory roles in inflammation and cell death. Among them, matrix metalloproteinase-9 (MMP9) is notably upregulated in the diabetic heart, where it promotes tissue remodeling and ROS generation. Typically latent, MMP9 is activated in pathological states like DM, contributing to cardiomyocyte death, though its role in ferroptosis is not fully understood. Our multi-omics analysis reveals an enrichment of polyunsaturated fatty acids—highly susceptible to peroxidation—and negatively charged lipids, establishing a pro-ferroptotic environment in the diabetic heart. Our findings identify ferroptosis as the predominant cell death mechanism in diabetic cardiomyopathy, with MMP9 as a central mediator. In vivo and in vitro studies confirm that MMP9 ablation mitigates T1DM-induced cardiac dysfunction, suggesting that MMP9 inhibition and lipid modulation hold potential as therapeutic strategies. These findings position ferroptosis and MMP9 as central mechanisms in diabetic cardiomyopathy and open new avenues for targeted intervention.